(Updated – August 29, 2023 6:58 AM EDT) Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the Company), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan), positioning Apellis for long-term success. This restructuring will include cost reduction initiatives that align with the Companys…
NEW DELHI: Three key executives have resigned from troubled edtech firm Byju’s as part of what the company has termed as a broader business restructuring.Under the new structure, four of its verticals have been consolidated into two segments – K-10 and exam prep. Byju’s did not elaborate on the matter but said in a statement…
According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses. (Image Credit: Rawpixel.com – Adobe.Stock.com) Apellis Pharmaceuticals Inc announced a corporate restructuring to drive growth of pegcetacoplan injection (SYFOVRE) and pegcetacoplan (EMPAVELI), which the…
Apellis Pharmaceuticals, Inc. announced a corporate restructuring to drive growth of SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan), positioning Apellis for long-term success. This restructuring will include cost reduction initiatives that align with the Company?s near-term priorities and are expected to result in up to $300 million in total cost savings through 2024. Key elements of…
Apellis Pharmaceuticals is laying off one quarter of its workforce in an overhaul of its business designed to focus resources on a newly approved vision loss drug. The job cuts announced Tuesday will affect about 225 employees. The company’s field-based sales staff and medical employees are minimally affected by the reorganization, which will be completed…
(Image Credit: AdobeStock/conceptcafe) Apellis Pharmaceuticals Inc announced a corporate restructuring to drive growth of pegcetacoplan injection (SYFOVRE) and pegcetacoplan (EMPAVELI), which the company said in a release would “position it for long-term success.” According to a company news release, the planned restructuring will include cost reduction initiatives that align with the companys near-term priorities and…
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38276 27-1537290 (State or Other…
Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G Focusing research initiatives on retina and CNS Anticipated total cost savings of up to $300 million through 2024, which includes an approximately 25% reduction in current workforce and a reduction in external expenses WALTHAM,…
Byju’s CBO, Two Other Senior Executives Quit Amid Restructuring Business NewsByju’s Chief Business Officer, Two Other Top Executives Quit Amid Restructuring ADVERTISEMENT 29 Aug2023, 2:01 PM IST 29 Aug 2023, 2:01 PM IST 29 Aug 2023, 2:01 PM IST WhatsApp X (was Twitter) Facebook Telegram Read the full article at: https://www.bqprime.com/business/byjus-chief-business-officer-two-other-top-executives-quit-amid-restructuring
In yet another setback for edtech player Byju’s, three senior executives, including Chief Business Officer Prathyusha Agarwal, have resigned amidst the company’s ongoing efforts to restructure and regain stability. Himanshu Bajaj, Business Head of Byju’s Tuition Centres, and Mukut Deepak, Business Head for Classes 4 to 10, are also among the executives who have tendered…